SCDS

Rancho Biosciences Welcomes BenevolentAI as New Member to Its Single Cell Data Science Consortium

Retrieved on: 
Wednesday, February 1, 2023
Bristol Myers Squibb, Novartis, Metadata, Janssen Pharmaceuticals, SCDS, SAN, Drug discovery, Biomedical Research, Johnson & Johnson, Data, Member, Pharmaceutical industry

Today, Rancho Biosciences is pleased to announce the addition of BenevolentAI as the fifth Member of the SCDS consortium.

Key Points: 
  • Today, Rancho Biosciences is pleased to announce the addition of BenevolentAI as the fifth Member of the SCDS consortium.
  • Due to the undeniable impact of single cell transcriptomics technology on drug discovery, there continues to be an exponential growth in the use of single cell sequencing methods by pharmaceutical companies.
  • The availability of ever-increasing amounts of single cell datasets in the public domain allows pharmaceutical companies to dramatically expand their universe of single cell experiments over those generated internally.
  • Prioritized by Members, Rancho will continue to deliver an ongoing stream of harmonized single cell datasets to the consortium.

Rancho Biosciences Launches the Single Cell Data Science Consortium With Four Charter Members

Retrieved on: 
Monday, May 2, 2022
Bristol Myers Squibb, GLOBE, Janssen Pharmaceuticals, Biomedical Research, Drug discovery, Johnson & Johnson, SAN, Novartis, LLC, Pharmacy, SCDS, Pharmaceutical industry

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Rancho Biosciences, a leading company in the field of data curation and data services, is pleased to announce the launch of its Single Cell Data Science (SCDS) pre-competitive consortium.

Key Points: 
  • SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Rancho Biosciences, a leading company in the field of data curation and data services, is pleased to announce the launch of its Single Cell Data Science (SCDS) pre-competitive consortium.
  • Due to the undeniable impact of single cell transcriptomics technology on drug discovery, there continues to be an exponential growth in the use of single cell sequencing methods by pharmaceutical companies.
  • The availability of ever-increasing amounts of single cell datasets in the public domain allows pharmaceutical companies to dramatically expand their universe of single cell experiments over those generated internally.
  • Leveraging this vast public data lake by finding, downloading, and curating single cell data is highly laborious and time-consuming compared to the resources for collectively analyzing data by scientists to gain value for biomedical research.

Global Hemoglobinopathies Markets, 2021-2028 - High Unmet Needs / Increasing R&D Investment / Initiatives to Improve Disease Awareness - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 5, 2021
Biotechnology, Pharmaceutical, Genetics, Health, CRISPR Therapeutics, Therapy, Bioverativ, CRISPR, USD, Diagnosis, Sickle cell disease, Anti-transglutaminase antibodies, CAGR, Excellent Care for All Act, FDA, SCAI, Hemoglobinopathy, Hematopoietic stem cell transplantation, National Heart, Lung, and Blood Institute, Access, Growth, Democratic republic, Awareness, ACCEL, Disease, SCD, NHLBI, Research, HB, SCDS, Government, Lung, Pharmaceutical industry, Vaccine

Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

Key Points: 
  • Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.
  • Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate.
  • The high patient population in low-income countries has encouraged market players and non-profit organizations to launch several initiatives to improve the access to the therapy.
  • Half of the global sickle cell anemia burden is present in India, Nigeria, and the Democratic Republic of the Congo